After dipping its toe into the BCMA water with an option to codevelop a bispecific antibody developed by TeneoOne, AbbVie has gone one step further – agreeing to buy the drug and the company ...

In early 2003, the team began to address the changes needed to implement EMAR and BCMA technology. The following issues were addressed before implementation. Staff nurses were involved in ...

Several targeting approaches are in development. BCMA is preferentially expressed on plasma cells and other mature B cells in blood 5. These cells originate with B-lymphocyte progenitors that ...

A prototype system was developed at the Colmery-O'Neil VAMC and later became the model for the award-winning bar-code medication administration (BCMA) system used throughout the Veterans Affairs ...

With the undeniable excitement in the BCMA field over the past few months, the BCMA Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize ...

Panelists discuss how recent clinical trials have demonstrated promising outcomes in late-line relapsed/refractory multiple myeloma (RRMM) with bispecific antibodies targeting B-cell maturation ...

The CAR-T cells used for myeloma target an antigen called B-cell maturation antigen (BCMA). The research team utilizes BCMA CAR-T cells produced from a manufacturer in the mainland. This product ...